查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1845329

脑膜炎脑膜炎治疗的全球市场:各治疗类型，各给药途径，各疫苗类型，各流通管道，各地区，机会，预测，2018年～2032年

Global Meningococcal Meningitis Treatment Market Assessment, By Treatment Type, By Route of Administration, By Vaccine Type, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 245 Pages | 商品交期: 3-5个工作天内

价格

全球脑膜炎球菌性脑膜炎治疗市场预计将从 2024 年的 4.3611 亿美元成长至 2032 年的 6.6929 亿美元，预测期内（2025-2032 年）复合年增长率 (CAGR) 为 5.50%。该市场正稳步增长，这得益于人们对脑膜炎球菌感染的认识不断提高、全球疫苗接种计划的加强以及疫情应对措施的改进。脑膜炎双球菌性脑膜炎是由脑膜炎球菌引起的急性细菌感染，其特征是起病迅速，如不及时治疗死亡率高。治疗通常包括使用强效抗生素，如青霉素、头孢曲松和氯霉素，并辅以支持性疗法。

疾病控制措施包括积极的干预和预防措施，例如在流行地区对密切接触者进行化学预防。政府主导的疫苗接种运动、诊断能力的提升以及对下一代疫苗和疗法研发投入的增加，进一步推动了市场成长。

本报告分析了全球脑膜炎双球菌性脑膜炎治疗市场，提供了市场概览，并按治疗类型、给药途径、疫苗类型、分销管道和地区划分了关键细分市场，以及公司简介。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 全球脑膜炎性脑膜炎治疗市场预测，2018年～2032年

  • 市场规模分析与预测
  • 市场占有率分析与预测
    • 各治疗类型
      • 抗生素疗法
      • 辅助性治疗
    • 各给药途径
      • 口服
      • 非口服(注射)
    • 各疫苗类型
      • 结合疫苗
      • 多糖类疫苗
      • 混合疫苗
    • 各流通管道
      • 医院药局
      • 线上药局
      • 零售药局
    • 各地区
      • 北美
      • 欧洲
      • 亚太地区
      • 南美
      • 中东·非洲
    • 各企业市场占有率分析(前五名公司以及其他- 各金额，2024年)
  • 2024年市场地图分析

第6章 北美的脑膜炎性脑膜炎治疗市场预测，2018年～2032年

  • 市场规模分析与预测
  • 市场占有率分析与预测
  • 各国市场评估
    • 美国
    • 加拿大
    • 墨西哥

第7章 欧洲的脑膜炎性脑膜炎治疗市场预测，2018年～2032年

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第8章 亚太地区的脑膜炎性脑膜炎治疗市场预测，2018年～2032年

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第9章 南美的脑膜炎性脑膜炎治疗市场预测，2018年～2032年

  • 巴西
  • 阿根廷

第10章 中东·非洲的脑膜炎性脑膜炎治疗市场预测，2018年～2032年

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非

第11章 需求供给分析

第12章 价值链分析

第13章 供应链分析

第14章 波特的五力分析

第15章 大环境分析

第16章 价格分析

第17章 市场动态

  • 市场促进因素
  • 市场课题

第18章 市场趋势与发展

第19章 法律规范

  • 临床试验
  • 法规当局的认证

第20章 专利的形势

第21章 案例研究

第22章 竞争情形

  • 前五名市场领导的竞争矩阵
  • 前五名参与企业的SWOT分析
  • 前10名市场主要企业的形势
    • Novartis AG
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Sanofi S.A.
    • Merck & Co., Inc.
    • Bio-Med (P) Limited
    • Wockhardt Ltd.
    • Walvax Biotechnology Co., Ltd.
    • JN-International Medical Corporation
    • Hualan Biological Vaccine Inc.

第23章 策略性建议

第24章 关于调查公司·免责声明

Product Code: MX13857

Global meningococcal meningitis treatment market is projected to witness a CAGR of 5.50% during the forecast period 2025-2032, growing from USD 436.11 million in 2024 to USD 669.29 million in 2032. The market has witnessed steady growth due to rising awareness of meningococcal infections, enhanced global immunization initiatives, and mounting efforts to improve outbreak response. Meningococcal meningitis is an acute bacterial infection caused by the bacterium Neisseria meningitidis, characterized by a rapid onset and high fatality rates if left untreated. The treatment typically involves the use of potent antibiotics such as penicillin, ceftriaxone, or chloramphenicol, accompanied by supportive treatment.

There are proactive interventions and prevention measures, such as chemoprophylaxis for close contact in areas with endemic outbreaks, that form part of the disease control measures. Government-sponsored immunization campaigns, improved diagnostic availability, and increased research and development expenditures for next-generation vaccines and treatments have further boosted the market's growth.

Increasing Prevalence of Meningococcal Meningitis Boosts Market Demand

The rising cases of meningococcal meningitis are driving market growth by bolstering the demand for effective treatment and vaccination solutions. As per the estimates of the World Health Organization (WHO), approximately 1 in 5 people across the globe who get bacterial meningitis suffer from severe complications and 1 in 6 people affected by the condition die. Since the disease remains a major public health concern with periodic outbreaks in many areas, governments and healthcare bodies globally are giving utmost importance to immunization campaigns to mitigate its impact. This has resulted in broader vaccine coverage and enhanced awareness campaigns, which are driving higher vaccination rates. Pharmaceutical companies are investing in the formulation of new and combination vaccines that offer broader protection from several meningococcal serogroups, thereby increasing vaccine uptake and compliance. Advances in diagnostic technologies also make the disease easier to detect and provide timely treatment, thereby fueling the market growth.

Increasing Emphasis on Innovation Supports Market Expansion

Technological developments and innovations in treatment regimens are the key drivers of the global meningococcal meningitis treatment market; however, there is an emerging trend of combination therapies which provide increased coverage against resistant strains and reduce regimen failures. Major pharma players are devoting greater attention to the development of newer antibiotic classes with greater efficacy and fewer side effects, resulting in the availability of advanced vaccines.

For instance, in February 2025, GlaxoSmithKline plc's Penmenvy, a 5-in-1 meningococcal vaccine targeting serogroups A, B, C, W, and Y, was approved by the United States Food and Drug Administration (US FDA) for individuals aged 10 to 25 years. Combining components of the company's existing Bexsero and Menveo vaccines, Penmenvy offers broad protection against invasive meningococcal disease (IMD) with fewer injections, aiming to improve vaccination rates.

At the same time, clinical practice guidelines are shifting the focus to antimicrobial stewardship and preventing the misuse of antibiotics. Hospitals and medical professionals alike are implementing stewardship programs that include timely diagnostic workups, optimal drug choice, and ongoing monitoring of clinical outcomes. This balanced strategy ensures improved patient care and reduces the development of antibiotic-resistant forms of the meningococcus.

Hospital Pharmacies Account for a Significant Share of the Market

Hospital pharmacies dominate the global market for treating meningococcal meningitis, with most treatment regimens starting with emergency treatments. Hospital environments play a critical role in the provision of parenteral antibiotics, the management of acute symptoms, and the stabilization of patients. Intensive care and close monitoring are necessary for many cases of meningitis, solidifying the status of hospital-administered treatment. Therefore, global health systems are focusing on improving hospital preparedness with investments in pharmacy automation, medicine stockpiling, and staff training. Additionally, leading hospital pharmacies are actively expanding their market reach, driving growth within this segment.

For instance, in March 2025, Apollo Health Co Ltd, the company behind the online platform Apollo 24/7 and Apollo Pharmacy, announced plans to expand its offline hospital pharmacy network in Bengal, India.

Meanwhile, retail pharmacies and online platforms are becoming increasingly important channels for prophylactic and follow-up medications in select markets, propelling their expansion.

North America Holds Major Share of Meningococcal Meningitis Treatment Market

North America holds the largest share of the meningococcal meningitis market due to its advanced healthcare infrastructure, high level of awareness for meningococcal diseases, and extensive availability of drugs and vaccines. Over the past few years, the threat of the condition has increased significantly.

For instance, in 2024, 503 probable and confirmed cases of meningococcal disease in the United States were reported, the largest number since 2013. The region receives good support from the government through vaccination activities and public health education that support timely immunization, thereby stimulating demand. Moreover, the presence of major pharma companies that invest heavily in research and development ensures ongoing technological advancements in meningococcal vaccines and treatments.

Meanwhile, Africa remains the most affected region globally, with major governments and healthcare organizations focusing on allocating significant resources to reduce mortality rates and boost treatment delivery.

Impact of the U.S. Tariff on Meningococcal Meningitis Treatment Market

Tariff-induced increases in the prices of active pharmaceutical ingredients (APIs) and medical devices create cascading effects across the treatment ecosystem. The most exposed of these include generic antibiotics that treat meningococcal infections, with narrow profit margins. The increased costs decrease the competitiveness of the manufacturers, and some might be forced to leave the market entirely. The latest tariff spikes in the United States highlight the vulnerabilities of the value chain of treating meningococcal meningitis, pushing the cost of inputs, the risk of supply chains, and uneven global access. Although shifts in manufacturing practices and supply diversification increase resilience, the short-term impact is a reduced supply and higher treatment costs, unless mitigated through strategic global collaboration and supportive domestic policies.

Key Players Landscape and Outlook

The key players in the market are focusing on research and development investments aimed at next-generation vaccines with enhanced safety profiles and larger serogroup coverages. Market growth remains positive with rising vaccination efforts, heightened health awareness, and the availability of better diagnostic technologies for detecting the disease in the initial stages. Public-private partnerships and collaborations with governments and NGOs are improving the availability of vaccines, particularly in high-risk areas. They are also expanding their geographical reach and reinforcing distribution networks to access emerging markets.

For instance, in May 2025, the US FDA approved the expansion of Sanofi's quadrivalent meningococcal vaccine, MenQuadfi, for use in infants as young as six weeks old. Previously, the vaccine was authorized for children two years of age and older. MenQuadfi helps protect against invasive meningococcal disease caused by serogroups A, C, W, and Y.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Treatment Type
      • 5.2.1.1. Antibiotics Therapy
        • 5.2.1.1.1. Third-generation Cephalosporins
        • 5.2.1.1.2. Penicillins
        • 5.2.1.1.3. Other Antibiotics
      • 5.2.1.2. Adjunctive Therapy
    • 5.2.2. Route of Administration
      • 5.2.2.1. Oral
      • 5.2.2.2. Parenteral (Injections)
    • 5.2.3. By Vaccine Type
      • 5.2.3.1. Conjugate Vaccines
      • 5.2.3.2. Polysaccharide Vaccines
      • 5.2.3.3. Combination Vaccines
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Online Pharmacies
      • 5.2.4.3. Retail Pharmacies
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Treatment Type
    • 5.3.2. By Route of Administration
    • 5.3.3. By Vaccine Type
    • 5.3.4. By Distribution Channel
    • 5.3.5. By Region

6. North America Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Treatment Type
      • 6.2.1.1. Antibiotics Therapy
        • 6.2.1.1.1. Third-generation Cephalosporins
        • 6.2.1.1.2. Penicillins
        • 6.2.1.1.3. Other Antibiotics
      • 6.2.1.2. Adjunctive Therapy
    • 6.2.2. Route of Administration
      • 6.2.2.1. Oral
      • 6.2.2.2. Parenteral (Injections)
    • 6.2.3. By Vaccine Type
      • 6.2.3.1. Conjugate Vaccines
      • 6.2.3.2. Polysaccharide Vaccines
      • 6.2.3.3. Combination Vaccines
    • 6.2.4. By Distribution Channel
      • 6.2.4.1. Hospital Pharmacies
      • 6.2.4.2. Online Pharmacies
      • 6.2.4.3. Retail Pharmacies
    • 6.2.5. By Country Share
      • 6.2.5.1. United States
      • 6.2.5.2. Canada
      • 6.2.5.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Meningococcal Meningitis Treatment Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Treatment Type
          • 6.3.1.2.1.1. Antibiotics Therapy
          • 6.3.1.2.1.1.1. Third-generation Cephalosporins
          • 6.3.1.2.1.1.2. Penicillins
          • 6.3.1.2.1.1.3. Other Antibiotics
          • 6.3.1.2.1.2. Adjunctive Therapy
        • 6.3.1.2.2. Route of Administration
          • 6.3.1.2.2.1. Oral
          • 6.3.1.2.2.2. Parenteral (Injections)
        • 6.3.1.2.3. By Vaccine Type
          • 6.3.1.2.3.1. Conjugate Vaccines
          • 6.3.1.2.3.2. Polysaccharide Vaccines
          • 6.3.1.2.3.3. Combination Vaccines
        • 6.3.1.2.4. By Distribution Channel
          • 6.3.1.2.4.1. Hospital Pharmacies
          • 6.3.1.2.4.2. Online Pharmacies
          • 6.3.1.2.4.3. Retail Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Supply Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

  • 17.1. Market Drivers
  • 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework

  • 19.1. Clinical Trials
  • 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

  • 22.1. Competition Matrix of Top 5 Market Leaders
  • 22.2. SWOT Analysis for Top 5 Players
  • 22.3. Key Players Landscape for Top 10 Market Players
    • 22.3.1. Novartis AG
      • 22.3.1.1. Company Details
      • 22.3.1.2. Key Management Personnel
      • 22.3.1.3. Products and Services
      • 22.3.1.4. Financials (As Reported)
      • 22.3.1.5. Key Market Focus and Geographical Presence
      • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 22.3.2. GlaxoSmithKline plc
    • 22.3.3. Pfizer Inc.
    • 22.3.4. Sanofi S.A.
    • 22.3.5. Merck & Co., Inc.
    • 22.3.6. Bio-Med (P) Limited
    • 22.3.7. Wockhardt Ltd.
    • 22.3.8. Walvax Biotechnology Co., Ltd.
    • 22.3.9. JN-International Medical Corporation
    • 22.3.10. Hualan Biological Vaccine Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 2. Global Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 3. Global Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 4. Global Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 5. Global Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 6. Global Meningococcal Meningitis Treatment Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 8. North America Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 9. North America Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 10. North America Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 11. North America Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. North America Meningococcal Meningitis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 14. United States Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 15. United States Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 16. United States Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 17. United States Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Canada Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 19. Canada Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 20. Canada Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 21. Canada Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 22. Canada Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Mexico Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 24. Mexico Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 25. Mexico Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 26. Mexico Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 27. Mexico Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Europe Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 29. Europe Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 30. Europe Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 31. Europe Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 32. Europe Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Meningococcal Meningitis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 35. Germany Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 36. Germany Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 37. Germany Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 38. Germany Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. France Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 40. France Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 41. France Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 42. France Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 43. France Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Italy Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 45. Italy Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 46. Italy Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 47. Italy Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 48. Italy Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. United Kingdom Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 50. United Kingdom Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 51. United Kingdom Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 52. United Kingdom Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 53. United Kingdom Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 54. Russia Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 55. Russia Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 56. Russia Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 57. Russia Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 58. Russia Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Netherlands Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 60. Netherlands Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 61. Netherlands Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 62. Netherlands Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 63. Netherlands Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Spain Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 65. Spain Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 66. Spain Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 67. Spain Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 68. Spain Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Turkey Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 70. Turkey Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 71. Turkey Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 72. Turkey Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 73. Turkey Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Poland Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 75. Poland Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 76. Poland Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 77. Poland Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 78. Poland Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 79. Asia-Pacific Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 80. Asia-Pacific Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 81. Asia-Pacific Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 82. Asia-Pacific Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 83. Asia-Pacific Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. Asia-Pacific Meningococcal Meningitis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 85. India Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 86. India Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 87. India Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 88. India Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 89. India Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. China Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 91. China Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 92. China Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 93. China Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 94. China Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 95. Japan Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 96. Japan Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 97. Japan Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 98. Japan Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 99. Japan Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. Australia Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 101. Australia Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 102. Australia Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 103. Australia Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 104. Australia Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 105. Vietnam Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 106. Vietnam Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 107. Vietnam Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 108. Vietnam Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 109. Vietnam Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. South Korea Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 111. South Korea Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 112. South Korea Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 113. South Korea Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 114. South Korea Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 115. Indonesia Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 116. Indonesia Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 117. Indonesia Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 118. Indonesia Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 119. Indonesia Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 120. Philippines Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 121. Philippines Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 122. Philippines Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 123. Philippines Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 124. Philippines Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 125. South America Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 126. South America Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 127. South America Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 128. South America Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 129. South America Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 130. South America Meningococcal Meningitis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 131. Brazil Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 132. Brazil Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 133. Brazil Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 134. Brazil Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 135. Brazil Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 136. Argentina Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 137. Argentina Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 138. Argentina Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 139. Argentina Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 140. Argentina Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 141. Middle East & Africa Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 142. Middle East & Africa Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 143. Middle East & Africa Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 144. Middle East & Africa Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 145. Middle East & Africa Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 146. Middle East & Africa Meningococcal Meningitis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 148. Saudi Arabia Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 149. Saudi Arabia Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 150. Saudi Arabia Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 151. Saudi Arabia Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 152. UAE Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 153. UAE Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 154. UAE Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 155. UAE Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 156. UAE Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 157. South Africa Meningococcal Meningitis Treatment Market, By Value, In USD Million, 2018-2032F
  • Figure 158. South Africa Meningococcal Meningitis Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 159. South Africa Meningococcal Meningitis Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 160. South Africa Meningococcal Meningitis Treatment Market Share (%), By Vaccine Type, 2018-2032F
  • Figure 161. South Africa Meningococcal Meningitis Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. By Treatment Type Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 163. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 164. By Vaccine Type Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 165. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024